Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

182.45USD
3:59pm EST
Change (% chg)

$0.02 (+0.01%)
Prev Close
$182.43
Open
$182.51
Day's High
$185.09
Day's Low
$182.02
Volume
1,342,077
Avg. Vol
1,193,527
52-wk High
$201.23
52-wk Low
$152.16

Latest Key Developments (Source: Significant Developments)

Abarca, Amgen Enter Outcomes-Based Agreement For Repatha
11:59am EST 

Feb 22 (Reuters) - Amgen Inc ::‍ABARCA SAYS SIGNED OUTCOMES-BASED CONTRACT WITH AMGEN FOR CHOLESTEROL-LOWERING DRUG, REPATHA​.  Full Article

Amgen Inc Q4 Loss Per Share $5.89
Thursday, 1 Feb 2018 04:01pm EST 

Feb 1 (Reuters) - Amgen Inc ::AMGEN QTRLY LOSS PER SHARE $5.89; QTRLY ADJUSTED EARNINGS PER SHARE $2.89; QTRLY REVENUE $5.80 BILLION, DOWN 3 PERCENT.AMGEN - QTRLY LOSS PER SHARE INCLUDES $6.1 BILLION CHARGE RELATED TO IMPACT OF U.S. TAX REFORM.AMGEN SEES 2018 TOTAL REVENUE $21.8 BILLION - $22.8 BILLION; SEES 2018 EARNINGS PER SHARE $11.18 - $12.36; SEES 2018 ADJUSTED EARNINGS PER SHARE $12.60 - $13.70.AMGEN SEES 2018 CAPITAL EXPENDITURES TO BE ABOUT $750 MILLION.AMGEN - ADDITIONAL $10 BILLION OF SHARE REPURCHASES AUTHORIZED.AMGEN - NEW INVESTMENT PLAN INCLUDES COMMITTING UP TO $300 MILLION TO BUILD NEW MANUFACTURING PLANT IN THE U.S..AMGEN - EXPECTS TO INVEST ABOUT $3.5 BILLION IN CAPITAL EXPENDITURES OVER NEXT 5 YRS, WITH ABOUT 75 PERCENT OF INVESTMENT IN THE U.S..AMGEN - EXPECTS TO FINALIZE EXACT LOCATION OF NEW MANUFACTURING PLANT IN Q2.AMGEN - INCREASING SIZE OF AMGEN VENTURES FUND, PROVIDING UP TO $300 MILLION GROWTH CAPITAL FOR EARLY STAGE, BIOTECH COS IN THE U.S..  Full Article

FDA Approves Addition Of Overall Survival Data To Kyprolis Label
Wednesday, 17 Jan 2018 04:15pm EST 

Jan 17 (Reuters) - Amgen Inc ::FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLIS® (CARFILZOMIB) LABEL.AMGEN INC - U.S. FDA APPROVED SUPPLEMENTAL NEW DRUG APPLICATION TO ADD OVERALL SURVIVAL DATA FROM PHASE 3 TRIAL TO PRESCRIBING INFORMATION FOR KYPROLIS.  Full Article

Amgen Expects To Launch Migraine Drug This Year
Tuesday, 9 Jan 2018 11:55am EST 

Jan 9 (Reuters) - Amgen Inc ::AMGEN CEO SAYS EXPECTS TO BE ABLE TO LAUNCH AIMOVIG FOR MIGRAINE THIS YEAR.AMGEN SAYS EXPECTS TO LAUNCH HUMIRA BIOSIMILAR OUTSIDE U.S. THIS YEAR.AMGEN CEO SAYS BUSINESS DEVELOPMENT DEALS TO REMAIN PRIORITY IN 2018.AMGEN CEO SAYS COMPANY IN STRONGER STRATEGIC POSITION AFTER TAX REFORM.  Full Article

Biocartis And Amgen Sign New Agreement
Tuesday, 9 Jan 2018 01:01am EST 

Jan 9 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND.AGREEMENT AIMED AT DEVELOPMENT OF IDYLLA(TM) CDX BIOMARKER TESTS .FINANCIAL DETAILS ON NEW CDX AGREEMENT WITH AMGEN ARE NOT DISCLOSED..  Full Article

FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Friday, 5 Jan 2018 09:00am EST 

Jan 5 (Reuters) - Amgen Inc ::FDA APPROVES XGEVA® (DENOSUMAB) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA.AMGEN INC - APPROVAL IS BASED ON DATA FROM PIVOTAL PHASE 3 '482 STUDY WHICH ENROLLED 1,718 PATIENTS.  Full Article

Amgen Expects To Incur GAAP Net Tax Expense Of Between $6 Bln And $6.5 Bln
Friday, 22 Dec 2017 04:22pm EST 

Dec 22 (Reuters) - Amgen Inc ::AMGEN - EXPECTS TO INCUR GAAP NET TAX EXPENSE OF BETWEEN $6 BILLION AND $6.5 BILLION - SEC FILING.AMGEN - EXPECTS TO HAVE ACCESS TO ITS ACCUMULATED GLOBAL CASH AS WELL AS ACCESS TO ITS FUTURE GLOBAL CASH FLOW.AMGEN - UNDER U.S. TAX REFORM LEGISLATION, THE COMPANY’S FUTURE U.S. INCOME GENERALLY WILL BE TAXED AT THE 21 PERCENT U.S. CORPORATE INCOME TAX RATE.AMGEN - UNDER TAX LEGISLATION,EX-U.S. INCOME, INCLUDING PUERTO RICO,GENERALLY WILL BE TAXED IN U.S. AT 10.5% REDUCED BY APPLICABLE FOREIGN TAX CREDITS.AMGEN - NET TAX EXPENSE CHARGE HAS NO IMPACT ON THE COMPANY’S PREVIOUSLY PROVIDED NON-GAAP GUIDANCE.AMGEN - GOING FORWARD, CO DOES NOT EXPECT AN INCREASE IN ITS NON-GAAP TAX RATES AS A RESULT OF THE U.S. TAX REFORM LEGISLATION.  Full Article

Amgen Announces 15 Percent Increase In Q1 2018 Dividend
Tuesday, 12 Dec 2017 04:00pm EST 

Dec 12 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES 15 PERCENT INCREASE IN 2018 FIRST QUARTER DIVIDEND.SETS QUARTERLY DIVIDEND OF $1.32PER SHARE.  Full Article

Kyprolis (Carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma
Monday, 11 Dec 2017 04:00pm EST 

Dec 11 (Reuters) - Amgen Inc ::KYPROLIS® (CARFILZOMIB) EXTENDED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN PHASE 3 ASPIRE TRIAL.AMGEN INC - STUDY MET KEY SECONDARY ENDPOINT OF OS.AMGEN INC - SAFETY DATA FROM ASPIRE WAS CONSISTENT WITH KNOWN SAFETY PROFILE OF KYPROLIS.  Full Article

Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint
Friday, 8 Dec 2017 01:11pm EST 

Dec 8 (Reuters) - Coherus Biosciences :COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM .COHERUS BIOSCIENCES SAYS ON DEC 7, JUDGE ISSUED UNDER SEAL REPORT AND RECOMMENDATION TO DISTRICT COURT IN RELATION TO PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS CO EXPECTS DISTRICT COURT TO DECIDE IN Q1 2018 WHETHER TO ADOPT MAGISTRATE JUDGE'S RECOMMENDATION - SEC FILING.COHERUS BIOSCIENCES SAYS ‍REPORT AND RECOMMENDATION ISSUED BY JUDGE WITH RESPECT TO LITIGATION BETWEEN AMGEN, AMGEN MANUFACTURING LTD, CO​.  Full Article

BRIEF-Abarca, Amgen Enter Outcomes-Based Agreement For Repatha

* ‍ABARCA SAYS SIGNED OUTCOMES-BASED CONTRACT WITH AMGEN FOR CHOLESTEROL-LOWERING DRUG, REPATHA​ Source text for Eikon: Further company coverage: